CTCX Carmell Corp.: Accounting Value per Share

Graphic logo of Carmell Corporation (CTCX)

Carmell Corporation (CTCX) is a reputable biopharmaceutical player in the tissue regeneration niche. The GURU.Markets website features this chart of the reported book value per share, where the parameter mark equals -0.07. The company develops unique plasma materials for surgery, ensuring stable demand. However, current developments are in the early stages and operating cash flow is zero, necessitating support from legacy capital.

Carmell Corp. (CTCX): Share Book Value from 02/21/2024 to 03/10/2025

carmellrx.com - analytical breakdowns and key metrics (CTCX)

- price and consensus price forecast:
Stock Price Carmell Corp|CTCX - Consensus Target
- market capitalization data:
Market Valuation Carmell Corporation|CTCX - Business Value
- book capitalization data:
Net Assets per Single Share Carmell|CTCX - Net Asset Value|Market Capitalization to Book Value Ratio carmellrx.com|CTCX - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Carmell Corporation|CTCX - Long-Term Debt to Capital|Short-Term Debt to Equity Carmell|CTCX - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Carmell Corporation|CTCX - Company Long-Term Liabilities|Company Short-Term Debts Carmell
Fundamental company valuation:Carmell Corp - CTCX
Manufactured products of Carmell

The book value per common share reflects the portion of equity attributable to each share after deducting all liabilities from the total asset value. The trend in this book value per common share allows for an assessment of the efficiency of R&D budget utilization by the Carmell Corporation (CTCX) biotech team, confirming the business's financial stability while navigating regulatory filters.

Competitors of Carmell Corporation (CTCX)

ASND: Book Value per Share|Madrigal Corp (MDGL) - Accounting Value per Share|Accounting Value per Share Corcept Therapeutics|RYTM (rhythmtx.com) - Equity per Share|Net Assets per Single Share Akero AKRO|Share Book Value Metsera, Inc.|MoonLake Pharma (MLTX) - Book Value per Share|Accounting Value of a Share Crinetics Corp (CRNX)|Book Value per Share NAMS (NewAmsterdam Pharma)|soleno.life - Book Value per Share|Net Assets per Single Share Amicus Therapeutics, Inc. (FOLD)|ETNB: Accounting Value of a Share|AGIO (Agios Pharmaceuticals Inc) - Net Assets per Single Share|Structure Corp (GPCR) - Accounting Value per Share|MDXG (MiMedx Group, Inc.) - Book Value per Share|Book Value per Share rezolutebio.com (RZLT)|Lexicon Pharmaceuticals, Inc. (LXRX) - Accounting Value per Share|Accounting Value of a Share MBX (MBX Biosciences, Inc.)|Altimmune Corp - Net Assets per Single Share|Accounting Value per Share Aardvark Pharma AARD|SGMT (Sagimet Biosciences) - Book Value per Share|bioagelabs.com (BIOA) - Net Asset Value per Share|BMEA - Accounting Value per Share|Quince Therapeutics, Inc. (QNCX) - Book Price of a Share|GUTS (Fractyl) - Book Value per Share|Book Value per Share vTv Therapeutics Inc|Book Value per Share Agape ATP Corporation (ATPC)|Net Assets per Single Share PLUR (pluri-biotech.com)|SYBX: Net Assets per Single Share|Lipocine Inc - Net Asset Value per Share|MTNB - Net Assets per Single Share|SPRB - Net Assets per Single Share|Galecto, Inc. - Book Value per Share|LUMO (lumos-pharma.com) - Net Assets per Share|ONVO: Net Assets per Single Share|Net Assets per Share RDUS